Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAPM on user fees

Executive Summary

The National Association of Pharmaceutical Manufacturers submitted comments to the Administrative Conference April 13 objecting to FDA's proposal for user fees. The association objected to FDA's proposal to have one set fee for NDAs and, although a fee was not proposed for ANDAs, questioned the equity of previous fee proposals for ANDAs. NAPM suggested that user fee programs should be centralized, "perhaps in OMB, where necessary expertise, if not already present, can be developed and applied to all agencies".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel